| 摘要 |
The kit comprises a first lyophilisate for preparing a first control having normal thrombocyte function, and a second lyophilisate for preparing a second control having abnormally reduced thrombocyte function. The first lyophilisate contains a buffer substance for maintaining a physiological pH, and an auxiliary substance for lyophilization. The second lyophilisate contains a buffer substance for maintaining a physiological pH, an auxiliary substance for lyophilization, and a direct inhibitor of thrombocyte aggregation. The kit comprises a first lyophilisate for preparing a first control having normal thrombocyte function, and a second lyophilisate for preparing a second control having abnormally reduced thrombocyte function. The first lyophilisate contains a buffer substance for maintaining a physiological pH, and an auxiliary substance for lyophilization. The second lyophilisate contains a buffer substance for maintaining a physiological pH, an auxiliary substance for lyophilization, and a direct inhibitor of thrombocyte aggregation in such an amount that a control is obtainable, where the control exhibits 70% of normal thrombocyte function. Each first and second lyophilisate additionally contains normal human plasma and human von Willebrand factor. The kit further comprises another lyophilisate for preparing another control having abnormally reduced thrombocyte function. Another lyophilisate contains the same or different direct inhibitor of thrombocyte aggregation with respect to the second lyophilisate. An independent claim is included for a method for preparing controls for a method for determining thrombocyte function. |
